Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Lecanemab path to approval

Lars Lannfelt • 16 Mar 2022
AD/PD 2022
Alzheimer’s Disease Dementia Antibodies Lecanemab

Lars Lannfelt, MD, PhD, Uppsala University, Uppsala, Sweden, comments on the next steps regarding using lecanemab in the clinical setting for the treatment of Alzheimer’s disease. Positive trial results are expected later this year, and it is anticipated that the monoclonal antibody targeting amyloid beta will be first approved in the US and later in Europe. Prof. Lannfelt believes that all Alzheimer’s disease patients should be able to receive lecanemab and benefit from the treatment; therefore, drug costs shouldn’t be high. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Disclosures

Prof. Lannfelt is a Co-Founder of BioArtic

More from Lars Lannfelt

Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease
1:54
Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease
Lars Lannfelt • 31 Oct 2024
The development of lecanemab for the treatment of early Alzheimer’s disease
5:37
The development of lecanemab for the treatment of early Alzheimer’s disease
Lars Lannfelt • 31 Oct 2024
Lecanemab: slowing the progression of AD and the potential for subcutaneous administration
3:26
Lecanemab: slowing the progression of AD and the potential for subcutaneous administration
Lars Lannfelt • 31 Oct 2024
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab
4:01
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab
Lars Lannfelt • 16 Mar 2022

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals